MarketScreener Homepage > Equities > Australian Stock Exchange > ALS Limited ALQ AU000000ALQ6

Report

End-of-day quote Australian Stock Exchange - 01/15
10.07	AUD		+1.51%

2020

ALS LIMITED : Ex-dividend day for interim dividend

2020

ALS : To Benefit As Mineral Exploration Heats Up

2020

ALS Posts Downbeat Fiscal H1 Net Profit; Shares Fall 3%

Summary

Financials

Sales 2021	1 764 M 1 359 M 1 359 M
Net income 2021	176 M 136 M 136 M
Net Debt 2021	788 M 607 M 607 M
P/E ratio 2021	27,6x
Yield 2021	1,88%

Sales 2022	1 913 M 1 473 M 1 473 M
Net income 2022	220 M 169 M 169 M
Net Debt 2022	724 M 558 M 558 M
P/E ratio 2022	22,2x
Yield 2022	2,41%

Capitalization	4 857 M 3 749 M 3 741 M
EV / Sales 2021	3,20x
EV / Sales 2022	2,92x
Nbr of Employees	-
Free-Float	97,3%

More Financials

Company

ALS Limited is a testing services provider. The principal activities of the Company are the provision of professional technical services in the areas of testing, measurement, inspection and monitoring; food and pharmaceutical quality assurance; mining and mineral exploration; commodity certification; equipment maintenance, and asset care operations. The Company's segments include: ALS Life Sciences, which provides...

Sector

Business Support Services

Calendar

More about the company

Notations Surperformance© of ALS Limited

Trading Rating :

Investor Rating :

More Ratings

All news about ALS LIMITED

2020	ALS LIMITED : Ex-dividend day for interim dividend	FA
2020	ALS : To Benefit As Mineral Exploration Heats Up	AQ
2020	ALS Posts Downbeat Fiscal H1 Net Profit; Shares Fall 3%	MT
2020	ALS LIMITED : half-yearly earnings release
2020	Denali Down 10% After Hours on Pause in DNL747 Studies	DJ
2020	NEWS HIGHLIGHTS : Top Company News of the Day	DJ
2020	ALS LIMITED : Ex-dividend day for final dividend	FA
2020	NEWS HIGHLIGHTS : Top Company News of the Day	DJ
2020	JEFF BEZOS : Top Company News of the Day	DJ
2020	Health Care Down As Analysts See Rally Overstretched -- Health Care Roundup	DJ
2020	ALS : Korea Midland power bans Australian lab ALS; police assess probe	RE
2020	ALS : Poised For Recovery	AQ
2020	ALS LIMITED : annual earnings release
2020	Korea South East Power Co bans Australian testing lab from coal tenders	RE
2019	Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy b..	RE

More news

News in other languages on ALS LIMITED

2020	ALS LIMITED : Veröffentlichung des Halbjahresergebnisses
2020	ALS LIMITED : publication des résultats semestriels
2020	IPO : Ina Invest Holding mit erfolgreichem Start an der Börse
2020	AXOVANT GENE THERAPIES LTD. : Veröffentlichung des Jahresergebnisses
2020	HUDSON LTD. : Veröffentlichung des Quartalsergebnisses

More news

Analyst Recommendations on ALS LIMITED

2013

Biogen says Lou Gehrig's disease drug fails in trial

More recommendations

Provided by Scoopnest.com

Chart ALS LIMITED

Duration : Period :

ALS Limited Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends ALS LIMITED

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	13
Average target price	9,80 AUD
Last Close Price	10,07 AUD
Spread / Highest target	9,24%
Spread / Average Target	-2,70%
Spread / Lowest Target	-45,4%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Raj Naran	Chief Executive Officer, MD & Director
Bruce John Phillips	Chairman
Luis Damasceno	Chief Financial Officer
John Francis Mulcahy	Independent Non-Executive Director
Charlie B. Sartain	Independent Non-Executive Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ALS LIMITED	4.79%	3 749



CINTAS CORPORATION	-7.75%	34 247
TELEPERFORMANCE	4.24%	20 080
UNITED RENTALS	10.02%	18 405
LG CORP.	21.14%	16 789
EDENRED	0.30%	13 835

More Results